Skip links

SciNeuro Pharmaceuticals and Alamar Biosciences Collaborate to Discover  Novel Therapeutic Antibodies for CNS Diseases

Fremont, CA and Rockville, MD – 15 February 2022 Alamar Biosciences (Alamar), a platform  company focused on transforming the field of proteomics to enable the early detection of cancer  and other diseases, and SciNeuro Pharmaceuticals (SciNeuro), a leader in the discovery and  development of innovative therapeutics for the treatment of neurological diseases, announced a multi-program collaboration and license agreement to discover and develop novel therapeutic  antibodies for targets selected by SciNeuro within the field of neurological diseases, based on  Alamar’s Attobody platform.

“We are excited about our collaboration with Alamar to discover novel therapeutic antibodies for  SciNeuro’s CNS programs,” commented Dr. Min Li, Founder and CEO of SciNeuro. “Alamar’s Attobody platform has already successfully generated promising antibodies against targets selected  by SciNeuro. We look forward to continuing our collaboration with Alamar to discover novel  therapeutic candidates.”

Alamar’s proprietary Attobody™ platform produces a highly diverse pool of antibodies with single digit picomolar affinity and exquisite specificity. Compared to traditional antibody engineering, the  Attobody platform deploys an accelerated antibody design and engineering process to generate novel  antibodies without the need for affinity maturation. 

Under the terms of the agreement, SciNeuro will have exclusive, worldwide rights to develop and  commercialize therapeutic antibodies resulting from the collaboration. Alamar will receive research  payments and is eligible to receive from SciNeuro downstream clinical and commercial milestone  payments and royalties on net sales of resulting products.

About Alamar Biosciences

Alamar Biosciences is a privately held life sciences company with a mission to transform the field of  proteomics to enable the early detection of cancer and other diseases. The company’s two proprietary  technology platforms, NULISA™ and Attobody™, work seamlessly with the latest advances in genomics  to achieve single-digit attomolar detection sensitivity, greatly surpassing the most sensitive protein  detection technology on the market today. The Attobodies have picomolar affinity and built-in high  specificity and have the potential to expand antibody therapeutics to many targets intractable with  conventional antibodies. For more information, please visit

For media queries, contact: 

Joe Barco 
VP Marketing 

About SciNeuro Pharmaceuticals

SciNeuro Pharmaceuticals is an innovation-driven, neuroscience-focused biopharmaceutical  company with corporate and R&D facilities located in China and the United States. The company has  established a broad portfolio of novel therapeutic candidates to address neurodegenerative and  other CNS diseases. SciNeuro focuses on targets that are supported by human biology and which  play a critical role in regulating foundation biology, to achieve better probability of success in clinical  development. SciNeuro is committed to delivering medicines that can make a difference to improve  the lives of patients around the world, transforming scientific discoveries into groundbreaking  therapies.  To learn more, visit

Media contact:
Lauren Arnold